BioMarin to acquire Amicus Therapeutics for $4.8B in all-cash deal at $14.50/share

BIOMARIN PHARMACEUTICAL INC

BioMarin acquires Amicus for $14.50/share in cash, total equity value ~$4.8B; expected Q2 2026 close.
Acquisition adds Galafold (Fabry) and Pombiliti+Opfolda (Pompe) products; Amicus's trailing 12-month revenue $599M.
BioMarin secures up to $3.65B bridge loan from Morgan Stanley to fund transaction.
Deal expected to be accretive to Non-GAAP diluted EPS in first 12 months post-close, substantially accretive from 2027.
Amicus board unanimously recommends; subject to Amicus stockholder approval and regulatory clearances.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

BIOMARIN PHARMACEUTICAL INC entered into Agreement and Plan of Merger with Amicus Therapeutics, Inc. valued at $14.50 per Share in cash (effective 2025-12-19).

Action: entry
Agreement: merger
Counterparty: Amicus Therapeutics, Inc.
Value: $14.50 per Share in cash
Effective: 2025-12-19

Exact text from the filing

On December 19, 2025, BioMarin Pharmaceutical Inc., a Delaware corporation (“ BioMarin ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Amicus Therapeutics, Inc. (the “ Company ” or “ Amicus ”), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of BioMarin (“ Merger Sub ”), providing for the merger of Merger Sub with and into Amicus (the “ Merger ”), with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-25-325856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.